Picture BIO Deutschland Corona Special Germany 2020 650x80px
Organisation › Details

iOnctura (Group)

iOnctura BV, headquartered in Geneva, Switzerland, was founded in June 2017 as a spin out from Merckand funded by M Ventures. It is a clinical stage biotechnology company developing a pipeline of next generation, differentiated molecules that are at the forefront of pioneering new therapies for the treatment of cancer. Each of iOnctura’s programs harness the combined effect of immune-mediated and direct anti-tumour activity and aim to deliver molecules with superior clinical efficacy and safety in oncology. The company’s lead program, IOA-244, will enter the clinic in Q1 2020. The study is aimed to clinically demonstrate for the first time that a highly selective PI3Kd inhibition not only drives an immunemediated response but also a direct anti-tumoural effect in a stratified patient population across multiple solid tumour indications. The Company’s second molecule is a novel autotaxin (ATX) inhibitor at IND stage for patients with solid tumours burdened with cancer-associated fibrosis. *


Period Start 2017-06-20 established (s-off
  Predecessor Merck KGaA
Products Industry cancer immunotherapy (immuno-oncology, I-O)
  Industry 2 drug development
Person Person Pickering, Catherine (iOnctura 201706– CEO + Co-Founder before Merck Head Global Oncology Licensing + BusDev)
Region Region Genève (Geneva) GE
  Country Switzerland
  Street 15 Avenue Sécheron
Campus Biotech Innovation Park, Bâtiment F2
  City 1202 Genève GE
    Address record changed: 2020-01-27
Basic data Employees n. a.
    * Document for �About Section�: iOnctura B.V.. (1/23/20). "Press Release: iOnctura Raises EUR 15 Million in Series A Financing to Progress Its Pipeline into Clinical Development". Amsterdam.
Record changed: 2020-01-27


Picture Fairtec GmbH We Optimise the ROI of Your Event 650x65px

More documents for iOnctura (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px

» top